IRLAB Therapeutics

According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual general meeting on May 22, 2024, the nomination committee shall, besides the Chair of the Board, consist of representatives of the three largest shareholders, or groups of shareholders, as per August 31, 2024.

The three largest shareholders or groups of shareholders have now appointed their representatives, thus the nomination committee ahead of the AGM 2025 has the following members:

• Daniel Johnsson, entrepreneur, business developer, investor, and board member of IRLAB. Appointed by a group of shareholders that consists of the company’s founders representing about 22 per cent of shares and votes; and
• Patrik Mossberg, CEO and chairman of Marinvest. Appointed by a group of shareholders representing about 15 per cent of shares and votes; and
• Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB’s founders. Appointed by a group of shareholders that consists of the company’s founders representing about 11 per cent of shares and votes;
• Carola Lemne, Chair of the Board of IRLAB Therapeutics AB.

The members of the nomination committee have been appointed by owners in IRLAB Therapeutics AB who represent a total of about 48 per cent of the total number of shares and votes in IRLAB Therapeutics AB as per August 31, 2024.

Information about the nomination committee’s work and the instruction to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee’s proposal will be presented in the summon to the annual general meeting 2025 and on the company’s web page, www.irlab.se. The annual general meeting will be held on May 21, 2025.

Shareholders who wish to submit proposals to the nomination committee shall do this in writing, no later than January 31, 2025, via e-mail ir@irlab.se.